KHNP to Cooperate in Production Isotopes for Cancer Treatment with France’s Framatome


Members of Korea Hydro & Nuclear Power and Framatome, a french nuclear power plant equipment company, pose for a photo at a memorandum of understanding signing ceremony in Paris, France, on April 17 (local time).
Members of Korea Hydro & Nuclear Power and Framatome, a french nuclear power plant equipment company, pose for a photo at a memorandum of understanding signing ceremony in Paris, France, on April 17 (local time).


Korea Hydro & Nuclear Power (KHNP) signed a business agreement with Framatome, a French nuclear power plant equipment company to cooperate in production of isotopes for cancer treatment in Paris, France, on April 17 (local time).


Under the agreement, the two companies will jointly conduct a technical feasibility study including the installation and design of production facilities for heavy water reactors (Wolseong Units 2, 3 and 4) in Korea to produce lutetium-177 (Lu-177).


Lutetium-177 is a theranostics radioisotope that can be treated at the same time as diagnosis, and is used to treat neuroendocrine and prostate cancer. Depending on which antibody it binds to, its applications are endless, so it is called an “isotope of dreams.”


In October 2023, KHNP inked a business agreement on technology development for production of lutetium-177 with the Korea Atomic Energy Research Institute, the Korean Society of Nuclear Medicine, and the Korean Association for Radiation Application to produce and utilize radioisotopes for cancer treatment.



Source link